# FGFR2

Source: https://onco.cc/targets/fgfr2/  
OnCo record `fgfr2` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FGFR2 is a growth receptor fused in bile-duct cancer and overproduced in gastric cancer.

## Summary

FGFR2 is a receptor tyrosine kinase that cancers activate in two different ways. Fusions, found in roughly 10 to 15 percent of intrahepatic cholangiocarcinoma, respond to the selective inhibitors pemigatinib and futibatinib; FGFR2b overexpression or amplification, found in about 3 to 8 percent of gastric cancers, is targeted by the antibody bemarituzumab (FORTITUDE-101 positive on overall survival in 2025) and by FGFR2b antibody-drug conjugates. FGFR3 alterations, present in 15 to 20 percent of urothelial cancers, are the related target of erdafitinib. Acquired kinase-domain mutations limit the durability of FGFR2 inhibitors, and hyperphosphataemia and eye toxicity are class effects. Endometrial cancer is a further setting under study. For a newcomer, FGFR2 is a growth receptor fused in bile-duct cancer and overproduced in gastric cancer, treatable in both.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: driver; kinase
- Symbol: FGFR2
- Class: kinase
- Biology: Receptor tyrosine kinase; FGFR3 alterations are the urothelial counterpart (erdafitinib).
- Where found: Cholangiocarcinoma; Gastric; Endometrial; Pancreatic ductal adenocarcinoma: gene fusion 0.2%; Gallbladder cancer: fusion, mutation or amplification 1%

## Notes

- Pancreatic ductal adenocarcinoma: FGFR2 fusions in about 0.2% overall and 5.2% of KRAS wild-type tumours (cBioPortal; Philip 2022); no FGFR inhibitor is approved in this disease, so patients are directed to tumour-agnostic or basket trials.
- Gallbladder cancer: no FGFR2 fusion among the structural variants deposited for cBioPortal gbc_mskcc_2022 and no recurrent structural variants in the cohort (Giraldo 2022); FGFR2 fusions belong to intrahepatic cholangiocarcinoma (Nakamura 2015).

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_2
- Wikipedia: https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_2

## Connected records

- biomarkers: [FGFR2 fusion or rearrangement](https://onco.cc/biomarkers/fgfr2-fusion-rearrangement/)
- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/), [KRAS wild-type pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-wild-type-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Rhabdomyosarcoma](https://onco.cc/cancers/rhabdomyosarcoma/)
- drugs: [ABSK061](https://onco.cc/drugs/absk061/), [Anlotinib](https://onco.cc/drugs/anlotinib/), [Bemarituzumab](https://onco.cc/drugs/bemarituzumab/), [CGT4859](https://onco.cc/drugs/cgt4859/), [Erdafitinib](https://onco.cc/drugs/erdafitinib/), [Futibatinib](https://onco.cc/drugs/futibatinib/), [HMPL-453](https://onco.cc/drugs/hmpl-453/), [Infigratinib](https://onco.cc/drugs/infigratinib/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Lirafugratinib](https://onco.cc/drugs/lirafugratinib/), [Nintedanib](https://onco.cc/drugs/nintedanib/), [Pemigatinib](https://onco.cc/drugs/pemigatinib/), [TAR-210](https://onco.cc/drugs/tar-210/), [therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)](https://onco.cc/drugs/therascreen-cdx/), [Tinengotinib](https://onco.cc/drugs/tinengotinib/), [TYRA-300](https://onco.cc/drugs/tyra-300/)
- companies: [Basilea Pharmaceutica](https://onco.cc/companies/basilea/), [Black Diamond Therapeutics](https://onco.cc/companies/black-diamond-therapeutics/), [Cogent Biosciences](https://onco.cc/companies/cogent-biosciences/), [Relay Therapeutics](https://onco.cc/companies/relay-therapeutics/), [Tyra Biosciences](https://onco.cc/companies/tyra-biosciences/)
- pathways: [FGF / FGFR signalling](https://onco.cc/pathways/fgfr-signalling/), [Gastric cancer (KEGG map)](https://onco.cc/pathways/gastric-cancer-signalling/), [PI3K / AKT / mTOR](https://onco.cc/pathways/pi3k-akt-mtor/), [Proteoglycans in cancer](https://onco.cc/pathways/proteoglycans-in-cancer/), [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/), [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/)
- trials: [A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations](https://onco.cc/trials/nct06378593/), [A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct05678270/), [FIGHT-202](https://onco.cc/trials/fight-202/), [FIRST-308](https://onco.cc/trials/first-308/), [FOENIX-CCA2](https://onco.cc/trials/foenix-cca2/), [FORTITUDE-101](https://onco.cc/trials/fortitude-101/), [SAFIR-ABC10](https://onco.cc/trials/safir-abc10/), [THOR](https://onco.cc/trials/thor/)
- key papers: [Biliary cancer: utility of next-generation sequencing for clinical management](https://onco.cc/key-papers/paper-javle-biliary-ngs-cancer-2016/), [Circulating tumor DNA profiling of advanced biliary tract cancers](https://onco.cc/key-papers/paper-mody-biliary-ctdna-profiling-jco-po-2019/), [Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer](https://onco.cc/key-papers/paper-burstein-tnbc-genomic-subtypes-ccr-2015/), [Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention](https://onco.cc/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/), [Genomic spectra of biliary tract cancer](https://onco.cc/key-papers/paper-nakamura-biliary-genomic-spectra-nat-genet-2015/), [Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma](https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/)
- terms: [FGFR2 fusions and rearrangements](https://onco.cc/terms/fgfr2-fusion/), [FGFR3 alterations (bladder cancer)](https://onco.cc/terms/fgfr3/), [Gene fusion](https://onco.cc/terms/gene-fusion/), [Intrahepatic, perihilar, distal and gallbladder cancer](https://onco.cc/terms/biliary-anatomy-subtypes/)
- ideas: [ctDNA-guided switching among FGFR inhibitors](https://onco.cc/ideas/idea-btc-ctdna-fgfr-resistance/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [FGFR3](https://onco.cc/targets/fgfr3-receptor/)
- people: [Lipika Goyal](https://onco.cc/people/lipika-goyal/), [Tanios Bekaii-Saab](https://onco.cc/people/tanios-bekaii-saab/), [Zev A. Wainberg](https://onco.cc/people/zev-wainberg/)
- institutions: [National Cancer Centre Singapore](https://onco.cc/institutions/nccs/)

---
JSON: https://onco.cc/api/v1/entities/fgfr2.json